This is the authors' abstract. We don't add key points for this paper.
Two panel discussions on non-animal New Approach Methodologies (NAMs) in regulatory safety assessments were held as webinars. These webinars were initiated and hosted by the scientific committee Pro Anima with contributions from international experts in the field. The panel discussions thoroughly explored the current landscape surrounding international regulatory acceptance and harmonisation of NAMs. The discussion focused on the regulatory challenges, stakeholder engagement, validation hurdles, and international efforts to facilitate a broader and more efficient adoption of NAMs in safety decision-making. The discussion also covered the role of emerging technologies such as artificial intelligence (AI) in advancing NAMs and provided insights into successful case studies, challenges and opportunities, and ongoing initiatives.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Courtot et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: